The labex gathers 15 teams belonging to 4 research units. They have an excellent track record in terms of publications , technology transfer and translational immunology.

Immuno-oncology
  • 5 teams UMR1232, CRCINA, Nantes
  • 1 team UMR1232, CRCINA, Angers
  • UMR 1236 Microenvironnement, Différentiation cellulaire, Immunologie et Cancer, Rennes
Immuno-transplantation and autoimmunity
  • 5 teams UMR1064, CRTI, Nantes
  • UMR 1227 LBAI Lymphocytes B et Autoimmunité, Brest
Oncogenesis and nuclear oncology
  • 2 teams UMR1232, CRCINA, Nantes

PARTNER 1 - Center for Research in Cancerology and Immunology Nantes/Angers (CRCINA)

Eight teams from the CRCINA contribute to the Labex IGO : team 1 (E. Scotet), team 2 (B. Dreno), team 3 (N. Labarriere), team 4 (M. Gregoire), team 5 (F. Altare), team 7 (Y. Delneste), team 9 (F. Vallette) and team 13 (F. Kraeber-Bodéré et M. Chérel). These teams have contributed to our improved understanding of the immunobiology of several human immune subsets and molecules (gd T cells, tumor-specific ab T cells, hemopoietic cytokines, innate receptors and myeloid cells and alpha-radioimmunotherapy). All these teams have been actively involved in the analysis of immune responses and immune regulation (including epigenetic regulation) in various physiopathological processes (tumors and inflammatory diseases). Several teams have implemented immunotherapeutic approaches in humans using gd T cell agonists, tumor vaccines, adoptive transfer of T cells and immunocytokine and alpha-radio immunotherapy thanks to tight collaborations with clinicians and private partners. Highly cited publications and innovative diagnostic and therapeutic approaches attest to their recognized expertise in the field.

PARTNER 2 - Center for research in transplantation & immunology (CRTI)

Five teams from the CRTI contribute to the Labex IGO : team 1 (M. C. Cuturi/R. Josien), team 2 (I. Anegon/ C. Guillonneau), team 3 (G. Blancho/B. Vanhove), team 4 (S. Brouard/D. Laplaud) and team 5 (P-A. Gourraud). These teams made major observations in : DC subsets and tolerogenic DCs in animal models and patients and identification of new regulators of immune responses, identification of CD8+ Tregs in rats and humans and analysis of their mechanism of action including new immunoregulatory molecules, generation of tolerogenic DCs and immune models of transgenic and KO rats, generation of new costimulation blocking agents, identification of MDSCs in transplantation and the use of humanized mice and primates in immune settings, identification of Bregs and new immunoregulatory molecules in tolerant patients and animal models, analysis of T CD8+ effector cells in transplanted patients and analysis of immune responses in multiple sclerosis, biology of endothelial cells and immune responses. CRTI teams also contribute to IGO with platforms and equipments.

PARTNER 3 - UMR 1236 / Microenvironnement, cell Différenciation, Immunology and Cancer (MICMAC)

UMR 1236 has been developing two main research axis focused on the biology of B‐cell lymphomas: the study of normal and malignant B‐cell differentiation and the study of normal and malignant B‐cell niches. It has significantly contributed to the characterization of human B‐cell subsets and identification of the key roles of infiltrating stromal cells, TFH and macrophages in lymphoma pathogenesis. The team has also developed translational projects in partnership with big pharmas : Evaluation of anti‐lymphoma drugs with a specific focus on pro-apoptotic molecules and immunomodulatory antibodies (anti‐CD137) ; Identification and characterization of lymphoma blood biomarkers using proteomic and transcriptomic approaches ; Clinical applications of mesenchymal stromal cells (MSC).

PARTNER 4 - UMR 1227 / Lymphocytes B & Autoimmunity (LBAI)

UMR1227 works on the study of normal and pathological B lymphocytes with applications to autoimmune diseases (rheumatoid arthritis, lupus and Sjögren’s syndrome), kidney graft rejection and lymphoproliferative B‐cell disorders. The team research extends from the most upstream approaches (CD5 B cells and epigenetic, regulatory B lymphocytes, the genetic control of BAFF, CD22 on B cells and its relationships with IVIg) to downstream ones (multi-center trials, patents in B‐cell immunotherapy, STREP).